The reasons driving alliances and deals between pharma and digital health have been well documented; the need for innovation without internal capability, the need to remain commercially competitive through the addition of data and analytics, the weight of evidence to prove value to regulators and payers, and the evolution into patient-centric organizations through new forms of engagement.
Indeed, some companies are investing in complete internal digital transformation to become value-driven innovators. In December, Japanese pharma major